Moderna (MRNA) Depreciation & Amortization (CF) (2018 - 2026)

Moderna has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $63.0 million in Q2 2026.

• Depreciation & Amortization (CF) for Q2 2026 came in at $63.0 million, up 10.53% year-over-year; the trailing twelve-month figure through Jun 2026 was $241.0 million (up 15.87% YoY), and the FY2025 annual result was $215.0 million, up 13.76% from the prior year.
• Depreciation & Amortization (CF) rose to $63.0 million in Q2 2026, from $59.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $249.0 million in Q3 2023 and troughed at $36.0 million in Q1 2024.
• A 5-year average of $83.1 million and a median of $65.0 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• The widest annual swing landed in 2022, when Depreciation & Amortization (CF) soared 426.67%; it then sank 79.12% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $80.0 million in 2022, then soared by 152.5% to $202.0 million in 2023, then tumbled by 70.3% to $60.0 million in 2024, then gained by 11.67% to $67.0 million in 2025, then declined by 5.97% to $63.0 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $63.0 million in Q2 2026, $59.0 million in Q1 2026, and $67.0 million in Q4 2025.